Project Grant HT94252410887
Award Date 9/1/24
Completion Date 8/31/27
Dollars Obligated $662K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Los Angeles, CA 90024, USA
Similar Awards
- This $1,464,751 Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports research conducted by the University of California, Los Angeles (UCLA) to develop adeno-associated virus (AAV) vectors targeted to muscle and muscle stem cells. The goal is to improve the therapeutic efficacy and safety of treatments for Duchenne muscular dystrophy. The award period runs from September 1, 2024 to August 31, 2027. As the prime awardee, UCLA...
- This Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) provides $551,250.00 to the University of California, Los Angeles (UCLA) to develop 3D-Bridge antisense oligonucleotides and a stem cell-targeting modality for skipping exons of Duchenne muscular dystrophy. The award period is from July 1, 2024 to June 30, 2026. Through this grant, UCLA will leverage its research and administrative capabilities to advance novel therapeutic...
- This federal Project Grant award, funded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), provides $551,216.00 to the University of California, Los Angeles (UCLA) to conduct research on elucidating the functional role of PPP1R1B-lncRNA in myocyte repair in Duchenne muscular dystrophy. The research project aims to advance the understanding of this critical biological mechanism with the goal of developing new therapeutic interventions for...
- The University of California, Los Angeles (UCLA) was awarded a $1,920,201.00 Project Grant from the Defense Health Agency (DHA) on August 1, 2023 under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant supports UCLA's research to conduct single nuclei transcriptome analysis of Duchenne muscular dystrophy (DMD) to identify disease-modifying targets. The research will be conducted at UCLA's facilities in Los Angeles, California over the 3-year period...
- The federal Project Grant award of $1,626,500.00 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports advanced biomedical research at the University of California, Los Angeles (UCLA). The grant, awarded on September 15, 2025, with a completion date of September 14, 2029, enables UCLA to conduct sophisticated scientific research and provide technical services across multiple medical domains. The research portfolio includes...
- This $563,484.00 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research conducted by Duke University to regulate skeletal muscle fibrosis in Duchenne muscular dystrophy. The two-year award, effective June 1, 2024 through May 31, 2026, will enable Duke University's research team to advance understanding and potential treatments for this debilitating neuromuscular disorder affecting military service members and...
- This federal Project Grant award of $345,664.00 from the Defense Health Agency, under the Military Medical Research and Development (CFDA 12.420) program, supports an advanced biomedical research initiative led by Royal Holloway University of London. The research project aims to develop an AAV-based microdystrophin gene therapy for Duchenne muscular dystrophy, with a focus on enhancing immune protection through capsid bioengineering. The award period spans from December 1, 2024 to November 30,...
- This federal Project Grant award, valued at $2,520,000.00, was issued by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The award supports advanced biomedical research initiatives focused on transforming healthcare for military service members and the broader public. The primary awardee, the University of California, Los Angeles (UCLA), will leverage its extensive facilities, diverse faculty expertise, and robust administrative capabilities...
- The University of California, Los Angeles (UCLA), through its Office of Research Administration, has been awarded a $2,351,564.00 Project Grant from the Defense Health Agency under the CFDA Program 12.420 - Military Medical Research and Development. This four-year grant, with a period of performance from August 15, 2023 to August 14, 2027, will support research targeting the EGFR signaling network in glioblastoma. As the prime grantee, UCLA will leverage its research facilities, faculty...
- The University of California, Los Angeles (UCLA), through its Office of Research Administration, was awarded a $1,366,628 Project Grant from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will fund research into the role of oxidative mitochondrial metabolism in resistance to androgen receptor inhibition from July 1, 2023 to June 30, 2026. As the prime awardee, UCLA will leverage its research facilities and faculty...